Novartis has agreed to sell 53.3 million or approximately 33% of Roche shares in a bilateral transaction to Roche for a total consideration of $20.7 billion.   Vas Narasimhan, CEO of Novartis, said, “After more than 20 years as a shareholder of Roche, we concluded that now is the right time to monetize our investment. Today’s announcement is consistent with our strategic focus and we intend to deploy the proceeds from the transaction in line with our capital allocation priorities to maximize s...